全文获取类型
收费全文 | 3262篇 |
免费 | 246篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 141篇 |
妇产科学 | 18篇 |
基础医学 | 698篇 |
口腔科学 | 11篇 |
临床医学 | 587篇 |
内科学 | 670篇 |
皮肤病学 | 31篇 |
神经病学 | 154篇 |
特种医学 | 99篇 |
外科学 | 198篇 |
综合类 | 322篇 |
预防医学 | 77篇 |
眼科学 | 7篇 |
药学 | 106篇 |
中国医学 | 21篇 |
肿瘤学 | 421篇 |
出版年
2024年 | 6篇 |
2023年 | 40篇 |
2022年 | 78篇 |
2021年 | 110篇 |
2020年 | 79篇 |
2019年 | 132篇 |
2018年 | 182篇 |
2017年 | 116篇 |
2016年 | 87篇 |
2015年 | 95篇 |
2014年 | 203篇 |
2013年 | 202篇 |
2012年 | 143篇 |
2011年 | 197篇 |
2010年 | 172篇 |
2009年 | 155篇 |
2008年 | 189篇 |
2007年 | 198篇 |
2006年 | 188篇 |
2005年 | 132篇 |
2004年 | 136篇 |
2003年 | 128篇 |
2002年 | 85篇 |
2001年 | 89篇 |
2000年 | 69篇 |
1999年 | 60篇 |
1998年 | 46篇 |
1997年 | 44篇 |
1996年 | 30篇 |
1995年 | 32篇 |
1994年 | 23篇 |
1993年 | 18篇 |
1992年 | 12篇 |
1991年 | 13篇 |
1990年 | 9篇 |
1989年 | 10篇 |
1988年 | 11篇 |
1987年 | 6篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1976年 | 1篇 |
1966年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有3565条查询结果,搜索用时 296 毫秒
51.
52.
目的:总结造血干细胞移植术后并发植入综合征的护理经验。方法经停用刺激因子、予甲基泼尼松龙冲击、连续肾脏替代治疗、提高胶体渗透压、氧疗等方案治疗,并给予积极正确的护理措施。结果3例病人均转危为安。结论植入综合征发病隐匿,与移植后的感染、移植物抗宿主病(GVHD)等并发症不易鉴别,容易错过诊断与治疗的最佳时机,延误诊治。护理人员作为与病人接触最直接者,应严密观察病情,使病人能得到及时、正确的诊治,确保痊愈出院。 相似文献
53.
《Biology of blood and marrow transplantation》2014,20(5):617-621
Hematopoietic cell transplantation (HCT) remains the only known curative therapy for many patients with hematologic, metabolic, and immunologic disorders. Furthermore, the use of HCT has increased with the emergence of HCT as a viable therapeutic option for older patients, those with significant comorbidities, and, with the demonstrated clinical effectiveness of alternative allogeneic donor sources, for those patients without a suitable sibling donor. The National Marrow Donor Program (NMDP) estimates that by 2020, it will facilitate 10,000 transplantations per year, double the number in 2010. To understand the needs of the HCT infrastructure to facilitate this number of transplantations, the NMDP organized the System Capacity Initiative 2020, centered on 6 working groups representing a diverse group of stakeholders. The Physician Workforce Group was tasked with addressing issues relating to recruitment and retention of transplantation physicians. We report here the results of our efforts and future initiatives. 相似文献
54.
55.
《Seminars in hematology》2017,54(1):25-32
The hematopoietic system has the remarkable ability to provide a lifelong supply of mature cells that make up the entire blood and immune system. However, similar to other adult stem cell niches, the hematopoietic system is vulnerable to the detrimental effects of aging. This is a substantial health concern as the trend for population aging continues to increase. Identifying mechanisms that underlie hematopoietic aging is vital for understanding hematopoietic-related diseases. In this review, we first discuss the cellular hierarchy of the hematopoietic system and the components that make up the surrounding hematopoietic niche. We then provide an overview of the major phenotypes associated with hematopoietic aging and discuss recent research investigating cell-intrinsic and cell-extrinsic mechanisms of hematopoietic stem cell (HSCs) aging. We end by discussing the exciting new concept of possibly reversing the HSC aging process along with outstanding questions that remain to be answered. 相似文献
56.
《Biology of blood and marrow transplantation》2014,20(7):908-919
Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving therapy that has traditionally been associated with high treatment-related mortality due to direct regimen toxicity and a high incidence of graft-versus-host disease. Historically, pre-existing renal insufficiency has been considered an exclusion criterion for transplantation. The advent of nonmyeloablative conditioning regimens as a less toxic modality for treatment has made HSCT more accessible to elderly patients and patients with comorbidities, such as renal impairment. However, there is no clear standard for how to dose preparative regimens for patients with chronic renal impairment who undergo HSCT. This article serves as a review of the current literature to provide dosing recommendations for commonly used preparative agents in the setting of chronic kidney disease, with the aim of providing optimal dosing for this patient population. 相似文献
57.
《Biology of blood and marrow transplantation》2014,20(9):1363-1368
We treated patients under age 50 years with iodine-131 (131I)–anti-CD45 antibody combined with fludarabine and 2 Gy total body irradiation to create an improved hematopoietic cell transplantation (HCT) strategy for advanced acute myeloid leukemia or high-risk myelodysplastic syndrome patients. Fifteen patients received 332 to 1561 mCi of 131I, delivering an average of 27 Gy to bone marrow, 84 Gy to spleen, and 21 Gy to liver. Although a maximum dose of 28 Gy was delivered to the liver, no dose-limiting toxicity was observed. Marrow doses were arbitrarily capped at 43 Gy to avoid radiation-induced stromal damage; however, no graft failure or evidence of stromal damage was observed. Twelve patients (80%) developed grade II graft-versus-host disease (GVHD), 1 patient developed grade III GVHD, and no patients developed grade IV GVHD during the first 100 days after HCT. Of the 12 patients with chronic GVHD data, 10 developed chronic GVHD, generally involving the skin and mouth. Six patients (40%) are surviving after a median of 5.0 years (range, 4.2 to 8.3 years). The estimated survival at 1 year was 73% among the 15 treated patients. Eight patients relapsed, 7 of whom subsequently died. The median time to relapse among these 8 patients was 54 days (range, 26 to 1364 days). No cases of nonrelapse mortality were observed in the first year after transplantation. However, 2 patients died in remission from complications of chronic GVHD and cardiomyopathy, at 18 months and 14 months after transplantation, respectively. This study suggests that patients may tolerate myeloablative doses >28 Gy delivered to the liver using 131I-anti-CD45 antibody in addition to standard reduced-intensity conditioning. Moreover, the arbitrary limit of 43 Gy to the marrow may be unnecessarily conservative, and continued escalation of targeted radioimmunotherapy doses may be feasible to further reduce relapse. 相似文献
58.
《Clinical Lymphoma, Myeloma & Leukemia》2019,19(6):365-371
IntroductionSurvival rate of patients with chemorefractory acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB) is poor. Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy in these patients.Patients and MethodsWe report a retrospective analysis of outcomes of therapy of 24 patients with AML or MDS-EB refractory to high-dose salvage chemotherapy or who had failed previous HCT, who received T-cell–replete HLA haploidentical HCT in aplasia after cladribine/cytarabine-based chemotherapy followed by reduced intensity or myeloablative conditioning. All patients had active disease before commencement of the treatment.ResultsOf the patients, 91.7% achieved complete remission (CR), whereas 2 patients (8.2%) died in aplasia. One-year relapse rate was 49.3%. Cumulative incidence of nonrelapse mortality (NRM) was 25.6%. In a subgroup of patients with HCT–comorbidity index score ≤ 3, NRM was 15.4%. Two-year overall survival and relapse-free survival were 30.6% and 22.6%, respectively. Incidence of grade 3 and 4 acute graft versus host disease was 21.3% and 8.3, respectively.ConclusionWe found that sequential therapy with HCT in aplasia after cladribine/cytarabine chemotherapy is feasible, results in high CR rates, and has acceptable toxicity profile; however, posttransplant relapse is common in patients treated with active disease. 相似文献
59.
60.
《Biology of blood and marrow transplantation》2013,19(8):1159-1166
We evaluated the pharmacodynamic relationships between mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil (MMF), and outcomes in 308 patients after nonmyeloablative hematopoietic cell transplantation. Patients were conditioned with total body irradiation ± fludarabine, received grafts from HLA-matched related (n = 132) or unrelated (n = 176) donors, and received postgrafting immunosuppression with MMF and a calcineurin inhibitor. Total and unbound MPA pharmacokinetics were determined to day 25; maximum a posteriori Bayesian estimators were used to estimate total MPA concentration at steady state (Css). Rejection occurred in 9 patients, 8 of whom had a total MPA Css less than 3 μg/mL. In patients receiving a related donor graft, MPA Css was not associated with clinical outcomes. In patients receiving an unrelated donor graft, low total MPA Css was associated with increased grades III to IV acute graft-versus-host disease and increased nonrelapse mortality but not with day 28 T cell chimerism, disease relapse, cytomegalovirus reactivation, or overall survival. We conclude that higher initial oral MMF doses and subsequent targeting of total MPA Css to greater than 2.96 μg/mL could lower grades III to IV acute graft-versus-host disease and nonrelapse mortality in patients receiving an unrelated donor graft. 相似文献